Assessment of Nitrofurantoin Efficacy on Treatment of Murine Model of Toxoplasmosis

Abstract

Toxoplasma gondii parasite is one of the world's most common parasites which is an intracellular parasite. The aim of this work is to investigate the effect of nitrofurantoin given at a dose of 100mg/kg(2mg for each mouse) , spiramycin given at a dose of 200mg/k.g (4mg for each mouse) and a combination of both(4 days post infection for 2 weeks) on the brain cyst count of infected mice (54 laboratory-bred Swiss albino mice). Mice were contaminated for 10 cysts for Toxoplasma gondii (ME 49 strain). Five aggregations for mice were utilized within those study,three bunches for them accepted medicines and the different two were ordinary Furthermore contaminated non treated aggregations. One bunch approached with spiramycin,other approached for nitrofurantoin, and the final one approached for the blending for both. The mice were sacrified then afterward 8 weeks. The blending for both pills made 4 days post spoiling for two weeks brought about critical diminishment in the mind growth check (78) with diminishment rate( 85. 2% ) contrasted with different gatherings. This goal that nitrofurantoin Might be an satisfactory antitoxoplasmic medication regardless same time its mix with spiramycin provided for those best result.

A new approach in treatment of chronic murine models of toxoplasmosis using nitrofurantoin antibiotic.

“…If the balance between the host immune responses and the parasite is broken, cyst rupture and parasite proliferation can ensue, leading to clinical reactivation [3]. In this study, we assessed the therapeutic antitoxoplasmic effect of nitrofurantoin in chronic toxoplasmosis which was mentioned before to have antitoxoplasmic action in vitro and in vivo in the acute stage in some handful of studies [18,25]. Including classic mainstay antitoxoplasmic treatment spiramycin, we designed a versatile drug regimen to explore the synergistic activities mentioned in the material and methods section.…”

“…T.gondii-induced MDA levels were decreased by nitrofurantoin, which also alleviated GSH depletion. Nitrofurantoin was reported to be effective in acute toxoplasmosis [18]. This study aimed to see how effective nitrofurantoin is as a treatment for chronic toxoplasmosis in mice, to see if it can compensate for the drawbacks of some of the other regularly used medications.…”

In-vivo Antiplasmodial Effect of Dihydroartemisinin-Piperaquine-Nitrofurantoin on Plasmodium berghei- Infected Mice

“…The mice were kept in cages under normal environmental conditions and were acclimated for 2 weeks with free access to feeds and water. The following doses of drugs were used: CQ (10 mg/kg) [18], NT (57.1 mg/kg) [19] and DP (1.71/13.7mg/kg) [20].…”